Rationale Effect of cannabinoid CB1 receptor deletion on cocaine's actions is controversial. This is partly based on findings in CB1-receptor-knockout (CB1 −/− ) mice with CD1 genetic background. Objectives In the present study, we used CB1 −/− mice with a C57BL/6J genetic background to further investigate the role of CB1 receptors in cocaine's action. Materials and methods Locomotor activity was assessed using AccuScan locomotor chambers. Brain extracellular dopamine (DA) levels were measured by in vivo microdialysis and by fast-scan cyclic voltammetry in the nucleus accumbens (NAc).
Cannabinoid CB1 receptors have become important targets in preclinical development of anti-addiction medications because their pharmacological blockade or genetic deletion significantly attenuates the effects of marijuana, opiates, nicotine, and alcohol (Maldonado et al. 2006; Fattore et al. 2007; Parolaro and Rubino 2008) . In contrast, the possible involvement of CB1 receptors in cocaine's actions is controversial. Early studies showed that blockade of CB1 receptors by SR141716A (rimonabant) had no effect on intravenous cocaine self-administration (Fattore et al. 1999; De Vries et al. 2001; Filip et al. 2006) , cocaine-induced conditioned place preference (CPP; Chaperon et al. 1998 ), cocaine's discriminative stimulus effects (Filip et al. 2006) , or cocaine-induced behavioral sensitization (Lesscher et al. 2005) . In addition, neither SR141716A nor AM251 (another CB1 receptor antagonist) affected cocaine-enhanced DA accumulation in the nucleus accumbens (NAc) (Caillé and Parsons 2006; Xi et al. 2006) .
In contrast to these negative findings, other studies demonstrated that AM251 and SR141716A (to a lesser extent) significantly inhibit cocaine self-administration under progressive-ratio (PR) reinforcement conditions (Soria et al. 2005; Xi et al. 2008) , cocaine-enhanced electrical brain-stimulation reward (Xi et al. 2008) , cocaine-induced behavioral sensitization (Filip et al. 2006) , and cocaine-or cocaine-associated cue-induced reinstatement of drug-seeking behavior (De Vries et al. 2001; Filip et al. 2006; Xi et al. 2006 ). In addition, SR141716A also significantly inhibits cocaine-, nicotine-, or alcohol-induced phasic DA release in the NAc (Cheer et al. 2007 ). These recent findings suggest an important role for CB1 receptors in cocaine's actions in animal models of drug addiction (Xi et al. 2008) . The reason for the discrepancy remains unclear but could be related to a recent finding that SR141716A is not as highly potent and highly selective a CB1 receptor antagonist in vivo as previously thought (Xi et al. 2008) .
In addition to the use of CB1 receptor antagonists, CB1
−/− mice have been used to study the role of CB1 receptors in drug reward and addiction (Ledent et al. 1999; Zimmer et al. 1999 ). There are presently three lines of CB1 −/− mice, with two different genetic backgrounds: CD1 (Ledent et al., 1999) and C57BL/6J (Zimmer et al. 1999) . Previous studies have shown that CB1 −/− mice with CD1 genetic background display similar responses to cocaine as their CB1
+/+ littermates in cocaine self-administration (Cossu et al. 2001) , cocaine-induced CPP and behavioral sensitization (Martin et al. 2000) , and in cocaine-enhanced NAc DA (Soria et al. 2005) , suggesting a limited role of CB1 receptors in cocaine's actions. However, this view has been challenged by other studies demonstrating that CD1 CB1 −/− mice display significant reductions in breakpoint levels for cocaine self-administration under PR reinforcement (Soria et al. 2005) , in cocaine-or amphetamine-induced hyperlocomotion and locomotor sensitization (Corbillé et al. 2007; Thiemann et al. 2008) , and in cocaine-induced changes in cortical dendritic arborization (Ballesteros-Yáñez et al. 2007) , when compared to CB1 +/+ mice. This is further supported by a recent finding that cocaine-induced CPP is abolished in CB1 −/− mice with C57BL/6J background, when cocaine doses were increased to 10 mg/kg (Miller et al. 2008) . These data suggest an important role for CB1 receptors in cocaine reward and addiction-related behaviors. The reasons for this discrepancy remain unclear. It could be related to differences in cocaine doses, mouse genetic backgrounds, experimental approaches, data analyses, or experimental conditions. Strikingly, CB1 −/− mice with CD1 versus C57BL/6J
backgrounds have been shown to exhibit different alterations in spontaneous locomotion, pain sensitivity, and several other behavioral responses to Δ 9 -tetrahydrocannabinol (Δ 9 -THC) (see Table 1 ). This suggests that mouse genetic backgrounds could be an important factor contributing to the discrepant findings described above. Since the majority of previous studies used CD1 CB1 
Basal locomotor activity ↓ (Zimmer et al. 1999 ; present study) ↑ (Ledent et al. 1999 ) Cocaine-induced hyperactivity ↓ (present study) Unchanged (Martin et al. 2000) ; ↓ (Corbillé et al. 2007 ) Behavioral sensitization to cocaine or amphetamine Unchanged (Martin et al. 2000) ; ↓ (Corbillé et al. 2007; Thiemann et al. 2008) Basal levels of extracellular DA in striatum ↓ (present study)
Unchanged (Soria et al. 2005 ) Cocaine-enhanced DA in striatum ↓ (present study) Unchanged (Soria et al. 2005 
Locomotor activity
Before drug administration, each animal was placed in locomotor detection chambers (Accuscan Instruments, Inc., Columbus, OH, USA) for 3 days (4 h/day) for environmental habituation. On each testing day, mice were placed in locomotor detection monitors for 1 h of habituation), and then each mouse was removed and given saline, cocaine (10 mg/kg, i.p.), or one dose (3, 10 mg/kg i.p.) of SR141716 (free base of SR141716A). Immediately after the drug injection, animals were placed back into the locomotor monitors. Data were collected in 10-min intervals using VersaMax version 3.0 software (Accuscan Instruments, Inc., Columbus, OH, USA). Total distance was used to evaluate the effects of different treatments on locomotor behavior.
In vivo microdialysis
Surgery All mice were surgically implanted with intracranial guide cannulae (MAB 4.15.IC, SciPro Inc., Sanborn, NY, USA) into the NAc. The surgery was performed under anesthesia with a ketamine hydrochloride (80 mg/ml) and xylazine hydrochloride (12 mg/ml) mixture (0.08 ml/10 g body weight, i.p.), using standard aseptic surgical and stereotaxic technique. The stereotaxic coordinates for the NAc were AP +1.4 mm, ML ±1.5 mm, DV −3.8 mm with an angle of 8°from vertical (Paxinos and Watson 1998) .
The guide cannulae were fixed to the skull with dental acrylic.
General procedure After 7 days of recovery from surgery, a probe (MAB 4.15.2.PES, SciPro Inc., Sanborn NY, USA) was inserted into the NAc at least 12 h before the experiments to minimize damage-induced DA release. On the day of the experiment, dialysis buffer (5 mM glucose, 2.5 mM KCl, 140 mM NaCl, 1.4 mM CaCl 2 , 1.2 mM MgCl 2 , 0.15% phosphate-buffered saline, pH 7.4) was perfused through the probe (2.0 μl/min) via syringe pump (Bioanalytical Systems, West Lafayette, IN, USA) beginning at least 2 h prior to sample collection. Dialysis samples were collected every 20 min into 10 μl 0.5 M perchloric acid to prevent DA degradation. After 1 h of baseline collection, animals received either vehicle, cocaine (10 mg/kg, i.p.), or SR141716 (3, 10 mg/kg, i.p.). After collection, samples were frozen at −80°C until analyzed.
Quantification of DA DA was measured in the dialysate with the ESA electrochemical detection system. The DA mobile phase contained 4.76 mM citric acid, 150 mM Na 2 HPO 4 , 3 mM sodium dodecyl sulfate, 50 mM EDTA, 10% methanol, and 15% acetylnitrile, pH 5.6. DA was separated using an MD-150×3.2-mm reversed-phase column from ESA Inc. (Chelmsford, MA, USA) and oxidized/ reduced using a Coulochem III detector from ESA Inc. Three electrodes were used: a preinjection port guard cell (+0.25 V) to oxidize the mobile phase, a reduction analytical electrode (E1, −0.1 V), and an oxidation analytical electrode (E2, 0.2 V). The area under curve (AUC) of the DA peak was measured using an "EZChrom Elite" ESA chromatography data system. DA values were quantified with an external standard curve (1-1,000 fM).
Brain slice preparation
Mice were killed by cervical dislocation and rapidly decapitated. The brains were removed and placed in chilled (4°C) and aerated (95% O 2 /5% CO 2 ) artificial cerebrospinal fluid (aCSF), comprised of (mM): NaCl (126); KCl (3.0); MgCl 2 (1.5); CaCl 2 (2.4); NaH 2 PO 4 (1.2); glucose (11.0); NaHCO 3 (25). Transverse brain slices containing the cerebral cortex and the striatum were cut (300 μm) in the chilled aCSF using a vibrating tissue slicer (Leica VT1000S). The brain slices were then transferred to a holding chamber containing aCSF, saturated with 95% O 2 / 5% CO 2 , at 32°C. Prior to initiating recordings, a single hemi-slice (i.e., one hemisphere) was submerged in a lowvolume (170 μl) recording chamber and continuously perfused with warm (30-32°C) aCSF at 2 ml/min. The aCSF was warmed using an in-line solution heater (TC-324B, Warner Instruments, Hamden, CT, USA).
Fast-scan cyclic voltammetry
Carbon-fiber electrode construction Fast-scan cyclic voltammetry was performed using carbon-fiber electrodes as described previously (Cahill et al. 1996; Heien et al. 2004) . Carbon fibers (7 μm diameter; Goodfellow Corp., Devon, PA, USA) were aspirated into glass capillary tubes, which were then pulled using a multistage patch pipette program on a Sutter P-97 electrode puller. The carbon fibers were trimmed to allow ∼20-50 μm to protrude from the glass capillary and then sealed in the glass by passing the assembly over a flame. Pipettes containing the carbon fiber were filled with a solution of 4 M potassium acetate and 150 mM KCl and attached to the headstage of a patch-clamp amplifier (Heka EVA-8). Voltammetric scans, stimulus waveform generation and timing, and data collection were performed using A/D boards (PCI 6052E and PCI-6711E, National Instruments, Austin, TX, USA) and custom LabView-based software (TarHeel CV, courtesy of Drs. Joseph Cheer and Michael Heien, University of North Carolina). All electrodes were tested for stable background currents and responsiveness in a laboratory beaker containing a DA (5 μM) solution prior to each experiment.
DA measurement in striatal slices Carbon-fiber tips were positioned between the separated tips of a bipolar stimulating electrode (FHC Inc., Bowdoin, ME, USA) using a stereo microscope. The carbon fibers were inserted ∼75-100 μm into the NAc slice, as previously described (Jones et al. 1995) . In initial experiments, we observed the most consistent and stable signals in the NAc core, just medial and dorsal to the anterior commissure. Therefore, all recordings were obtained from this locus. Voltammetric scans from −0.4 to 1.0 V and back were performed at 400 V/s (7-ms scan duration) at a frequency of 10 Hz. A 5-s measurement (50 scans) of background current was taken prior to electrical stimulation of the brain slice and subtracted from the voltammetric scan obtained at the signal peak during the electrical stimulation. The remaining currents following background subtraction were then used to generate a voltammogram (plotting current versus voltage) for each signal. All signals matched the expected oxidation and reduction signals of DA (Jones et al. 1995; Cahill et al. 1996) . Electrical stimulation consisted of a single 1-ms biphasic pulse that was offset from the voltammetric scans. Electrical stimulation current intensity was varied from 0.1 to 1 mA in order to construct inputoutput curves for each placement in the striatal slice. Time constants (τ) for the decay phase of each DA signal were obtained by fitting a single exponential function y ¼ A Àt=t À Á using a least squares minimization algorithm (WCP, Dr. John Dempster, Strathclyde Institute for Biomedical Sciences, Glasgow, UK, http://spider.science.strath.ac.uk).
Initial comparisons of the sum of squares (F test) between single and double exponential functions (Prism v. 5.0) confirmed that the decay phase was best fit by a single exponential in all cases. It has been previously demonstrated that the first-order rate constant (k or 1/τ) obtained using this approach provides an index of the efficiency (V max /K m ) of DA clearance mediated via the DA transporter, at low DA concentrations (Sabeti et al. 2002) . 
Drugs

Histology
Following completion of in vivo microdialysis, mice were decapitated and brains were removed and placed in 10% formalin for 1 week. The tissue was blocked around the NAc and coronal sections (100 μm thick) made by vibratome. The sections were stained with cresyl violet. Only those animals that had been implanted in the desired NAc locus were used in the study.
Data analyses
All data are presented as means (±SEM). One-way (genotype), two-way (genotype × time, or genotype × stimulus intensity for input-output relationships in slice studies), or three-way (genotype × treatment × time) analysis of covariance (ANCOVA) were used to analyze the data (more details described in "Results" below). Preplanned individual group comparisons were carried out using the Bonferroni statistical procedure.
Results
Basal locomotion and cocaine-induced hyperlocomotion is attenuated in CB1
−/− mice Figure 1 shows the effect of cocaine (10 mg/kg, i.p.) or vehicle on locomotion in CB1 +/+ and CB1 −/− mice, indicating a significant attenuation of basal and cocaineaugmented locomotion in CB1 −/− mice. Three-way ANCOVA with repeated measures over time and baseline values as covariates for the data shown in Fig. 1a (F 8, 256 =7.9, p<0.001). Further data analyses revealed a significant reduction in either basal levels of extracellular DA (Fig. 2b: F 1, 34 =4 .51, p<0.05, one-way ANOVA) or cocaine-enhanced NAc DA ( Figure 3a shows representative voltammetric signals, illustrating that DA release elicited by single-pulse electrical stimulation was significantly lower in a CB1 −/− mouse than in a CB1 +/+ mouse. Figure 3b shows mean DA release elicited by single-pulse electrical stimuli across a range of stimulus intensities, demonstrating a significant reduction in evoked DA release in CB1 −/− mice compared to CB1 +/+ mice (F 1, 330 =47.70, p<0.001, repeatedmeasures ANOVA). Figure 3c shows mean decay time constants (τ) of the DA signal in both CB1 +/+ and CB1 −/− mice (t=0.2399, p=NS), indicating no difference in DA uptake between the two groups of mice.
SR141716 inhibits locomotion in CB1 +/+ mice Figure 4 shows that the CB1 receptor antagonist SR141716 (3 or 10 mg/kg, i.p.) significantly inhibited locomotor activity in CB1 +/+ mice. Two-way ANOVA with repeated measures over time and subjects for the data shown in Fig.   Fig. 1 Basal and cocaine-enhanced locomotor activity in CB1 +/+ and CB1 −/− mice. a shows basal locomotion data (distance) and cocaineor saline-induced locomotion in CB1 +/+ and CB1 −/− mice. b shows mean basal locomotion in CB1 +/+ and CB1 −/− mice, indicating a significant reduction in locomotion in CB1 −/− mice relative to their wild-type CB1 +/+ littermates. c shows percent change from baseline in cocaine-induced locomotion, indicating that the duration of cocaineenhanced locomotion was shorter in CB1 −/− mice than in CB1 (Fig. 5) . Two-way ANOVA with repeated measures over time for the data shown in Fig. 5a revealed a statistically significant treatment main effect (F 1, 15 =12.10, p<0.01) and time main effect (F 17, 255 =4.43, p<0.05). One-way ANOVA for the AUC data shown in Fig. 5b revealed a statistically significant reduction (F 1, 15 =12.19, p<0.01) in extracellular DA after SR141716 administration. Figure 6 shows microdialysis probe locations in the mouse ventral striatum. Figure 6a shows a representative probe track. The active semi-permeable probe membranes of the microdialysis probes were located within the NAc core and shell (Fig. 6b ). There were no differences in placement of microdialysis probes between CB1 +/+ and CB1 −/− mice.
Histology
Discussion
The present study demonstrates that CB1 −/− mice bred on a C57BL/6J genetic background display a significant reduction in both basal levels of and cocaine-enhanced locomotion and in extracellular NAc DA, compared to their CB1
littermates. In vitro fast-scan cyclic voltammetry demonstrated that the reduced extracellular DA is likely due to a reduction in basal DA release rather than an increase in DA clearance. These observations in CB1 −/− mice are supported by the finding that pharmacological blockade of CB1 receptors by SR141716 also inhibited locomotion and NAc DA release in CB1 +/+ mice. Together, these data suggest an important role for CB1 receptors in maintaining locomotor activity and DA tone, under both basal and cocaine-stimulated conditions. Locomotion has been widely used to study neural mechanisms underlying addictive drug action (Cornish and Kalivas 2001) . The high density of CB1 receptors in the basal ganglia and cerebellum suggests involvement of CB1 receptors in locomotion (Mailleux and Vanderhaeghen 1992; Tsou et al. 1998 ). However, the reported effects of cannabinoid agonists on locomotor activity are varied. Previous studies have reported increases (Sañudo-Peña et al. 2000) , decreases (Ferrari et al. 1999; Shi et al. 2005; Wu and French 2000) , and biphasic dose-dependent effects of cannabinoid agonists on locomotion (Sulcova et al. 1998; Abel 1970 ), which appears to be largely dosedependent (Muschamp and Siviy 2002; Järbe et al. 2006; Pandolfo et al. 2007 ). In the present study, CB1 −/− mice displayed decreased basal locomotor activity compared with their wild-type CB1 +/+ littermates. This is consistent with a previous report on CB1 −/− mice with C57BL/6J
background (Zimmer et al. 1999 ), but contrasts with findings in CB1 −/− mice bred on a CD1 background in which increased basal locomotion was observed (Ledent et al. 1999 ; Table 1 ). Consistent with our finding in CB1 −/− mice, the CB1 receptor antagonist SR141716 inhibited spontaneous Fig. 4 Effect of SR141716 on locomotor activity in CB1 +/+ mice. a shows locomotion after SR141716 (3, 10 mg/kg, i.p.) or vehicle. b shows overall mean locomotion (AUC data) after SR141716 or vehicle administration. ***p<0.001, compared to vehicle group mice (n=28 slices from eight subjects) relative to CB1 +/+ mice (n=23 slices from six subjects). c shows the mean decay time constants (tau, τ) of the DA signals, indicating that DA clearance (or uptake) was not different between CB1 +/+ (n=18 slices from six subjects) and CB1
−/− mice (n=15 slices from four subjects). **p<0.01, ***p<0.001, compared to CB1 +/+ mice, repeated-measures ANOVA locomotion in C57BL/6J (present study) and other mouse strains (Compton et al. 1996) , as well as in rats (Järbe et al. 2002 (Järbe et al. , 2006 Gardner and Mallet 2006) . These data suggest that activation of CB1 receptors under physiological conditions tends to activate locomotion and may therefore contribute to the maintenance of normal locomotor activity in wild-type mice or rats. Given that Δ
9
-THC and other cannabinoid agonists such as WIN55,212-2, CPP55940, and HU-210 are non-selective cannabinoid receptor agonists (Pertwee 2005), we speculate that locomotion reduction produced by these compounds could be mediated by activation of other non-CB1 receptors.
Endocannabinoid involvement in cocaine-induced hyperlocomotion
In addition, endocannabinoids may also be involved in cocaine-induced hyperlocomotion. In the present study, we found that CB1 −/− mice displayed a significantly reduced locomotor response to acute cocaine as compared to their CB1 +/+ littermates. This finding is in contrast to a previous report by Martin et al. (2000) but is consistent with a recent report by Corbillé et al. (2007) . In addition, CB1 −/− mice have been shown to display impaired locomotor sensitization to cocaine or D-amphetamine (Corbillé et al. 2007; Thiemann et al. 2008) . Further, the novel CB1 receptor antagonist AM251 blocks cocaine or D-amphetamineinduced locomotor sensitization in CB1 +/+ mice (Corbillé et al. 2007 ). These findings suggest that cannabinoid mechanisms acting via CB1 receptors play an important role in mediating psychostimulant-induced hyperlocomotion. We note, however, that SR141716A has been reported to have no effect on acute cocaine-induced locomotor stimulation (Przegaliński et al. 2005; Lesscher et al. 2005) but attenuates chronic cocaine-induced motoric sensitization in rats (Filip et al. 2006; Gerdeman et al. 2008) . In addition, the cannabinoid agonists HU210 and WIN55,212-2 have been reported to significantly attenuate cocaineinduced hyperlocomotion in rats (Ferrari et al. 1999; Przegaliński et al. 2005) . The reasons for such discrepant findings are unclear. Many factors-including species differences (rats vs. mice), different neural mechanisms Endocannabinoid modulation of DA release
It is well documented that increases in extracellular DA levels in both the dorsal and ventral striatum are related to the rewarding and psychomotor-stimulating effects of cocaine and other psychostimulants (Wise 2005 -THC or other cannabinoid agonists produce an increase in either striatal DA release or ventral tegmental area (VTA) DA neuron activity (Chen et al. 1990; French 1997; Tanda et al. 1997; Melis et al. 2000) , an effect that is blocked by SR141716A (French 1997; Tanda et al. 1997) . These data suggest that activation of CB1 receptors increases, whereas inactivation decreases, basal DA release in the dorsal and/or ventral striatum. This conclusion is further supported by our finding that pharmacologic blockade of CB1 receptors by SR141716 significantly lowered extracellular NAc DA levels in CB1 +/+ mice. This finding is in contrast to previous findings in rats that SR141716A or AM251 failed to lower extracellular NAc DA (Caillé and Parsons 2006; Xi et al. 2006) , perhaps suggesting a difference between rats and mice in cannabinoid tone on DA release.
The mechanisms by which cannabinoids modulate DA release remain unclear. Anatomical evidence indicates that midbrain DA neurons have very low CB1 receptor levels (Mailleux and Vanderhaeghen 1992; Tsou et al. 1998; Julian et al. 2003) , with much higher levels observed on axon terminals impinging upon these cells (Mátyás et al. 2008) . This suggests that cannabinoids may not exert direct actions on midbrain DA neurons (Maldonado et al. 2006 for review). Instead, the high densities of CB1 receptors expressed on both glutamatergic and GABAergic neurons in the VTA and NAc (Szabo et al. 2002; Julian et al. 2003; Riegel and Lupica 2004; Köfalvi et al. 2005; Mátyás et al. 2006; Corbillé et al. 2007 ) appear indicative of indirect cannabinoid modulation of DA release. Cannabinoid activation of VTA CB1 receptors appears to produce inhibition of GABA release (Szabo et al. 2002; Riegel and Lupica 2004) . This may result in increased VTA DA neuronal activity or striatal DA release by disinhibition. In addition, increased VTA DA neuronal activity may augment endocannabinoid release resulting in inhibition of both GABAergic and glutamatergic inputs to VTA DA neurons Lupica and Riegel 2005; Maldonado et al. 2006) . The final net effect on VTA DA neuron activity would depend on the functional balance between these opposite actions . Finally, increased NAc DA may also stimulate endocannabinoid release from postsynaptic medium-spiny GABAergic neurons (Giuffrida et al. 1999; Patel et al. 2003; Centonze et al. 2004) , which may then activate presynaptic CB1 receptors, producing an inhibition of glutamate release from corticostriatal glutamatergic terminals (Robbe et al. 2001 (Robbe et al. , 2002 . This decreased glutamate would lower the excitability of medium-spiny GABAergic neurons, thereby decreasing inhibitory GABAergic input from NAc to VTA DA neurons (Szabo et al. 2002) . Accordingly, deletion of CB1 receptors might well decrease basal NAc DA release, as observed in the present study.
Endocannabinoid involvement in cocaine-enhanced DA release
We also found in the present study that the striatal DA response to acute cocaine (10 mg/kg i.p.) was significantly reduced in CB1 −/− mice compared to CB1 +/+ mice. This is consistent with a recent finding that SR141716A significantly inhibits cocaine-, nicotine-, or alcohol-induced phasic DA release in rats as assessed by fast-scan cyclic voltammetry (Cheer et al. 2007 ) but contrasts with the finding that cocaine produces a similar increase in extracellular NAc DA in both CB1 +/+ and CB1 −/− mice with CD1 genetic background (Soria et al. 2005) , and with reports that CB1 receptor antagonists fail to alter cocaine-induced increases in extracellular NAc DA in rats (Caillé and Parsons 2006; Xi et al. 2006) . Many factors could account for such discrepancies, including species differences (rats vs. mice), genetic backgrounds (C57BL/6J vs. CD1), experimental methods (voltammetry vs. microdialysis), or placement of microdialysis probes (dorsal vs. ventral striatum). Whatever the reasons for the discrepancies in the literature, the present findings suggest an important role for CB1 receptors in cocaine-enhanced NAc DA. Given that cocaine-enhanced DA levels result from blockade of DA re-uptake (Wise 2005) , reduced basal DA release in CB1 −/− mice may underlie the observed reduction in cocaine's actions on DA release and locomotion observed in CB1 −/− mice in the present study. Finally, the present data speak to the importance of background genetic strain in the functional consequences of gene deletion.
In conclusion, the present study demonstrates that CB1
−/− mice on a C57BL/6J background (Zimmer et al. 1999 ) display a significant reduction both in basal DA release and locomotor activity, as well as in cocaine-induced increases in locomotion and extracellular NAc DA. These findings, combined with pharmacological findings, support an important role for endocannabinoid-CB1 receptor substrates in cocaine addiction.
